613 - 3SBio
Latest Information Update: 28 Sep 2024
At a glance
- Originator 3SBio
- Class Antipyretics; Antirheumatics; Monoclonal antibodies
- Mechanism of Action Interleukin 1 beta inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Gouty arthritis
- No development reported Autoimmune disorders; Fever; Juvenile rheumatoid arthritis
Most Recent Events
- 28 Sep 2024 No recent reports of development identified for clinical-Phase-Unknown development in Fever in China (Parenteral)
- 28 Sep 2024 No recent reports of development identified for clinical-Phase-Unknown development in Juvenile-rheumatoid-arthritis in China (Parenteral)
- 28 Oct 2023 No recent reports of development identified for preclinical development in Autoimmune-disorders in China (Parenteral)